Evidence & Research Status
Educational overview of a compound studied in metabolic and longevity research. Everything here reflects the published literature — largely preclinical, with early and mixed human data — and is for…
Evidence Level reflects the general state of published research for this compound category and is not a claim about the safety, efficacy, or approval status of any product sold on this site. All compounds are offered strictly for research use.
By Charles Fowler, Founder of Portal to Wellness · Last reviewed: June 2026 · ~6 min read
Educational overview of a compound studied in metabolic and longevity research. Everything here reflects the published literature — largely preclinical, with early and mixed human data — and is for research and educational purposes only. Not medical advice or a dosing instruction.
MOTS-c is one of the most genuinely novel compounds in longevity research, because of where it comes from. If you’ve read our piece on why researchers study NAD+, MOTS-c is a natural companion — both sit at the mitochondrial heart of the aging conversation.
Key Takeaways
- MOTS-c is a mitochondrial-derived peptide studied for its role in cellular energy regulation.
- Its proposed mechanism runs through the AMPK signaling pathway.
- Researchers describe it using an “exercise mimetic” framing based on its metabolic effects.
- It’s positioned within PTW’s broader cellular-energy and longevity research category.
What MOTS-c is
MOTS-c is a 16–amino-acid peptide encoded not by nuclear DNA but by mitochondrial DNA (within the 12S rRNA region). That makes it part of a newer class called mitochondrial-derived peptides — molecules suggesting that mitochondria aren’t just cellular power plants but active signaling hubs that help coordinate whole-body metabolism.
How it works — the AMPK pathway
In research, MOTS-c primarily acts through the folate–AICAR–AMPK pathway. AMPK is a master metabolic sensor; activating it is associated in studies with increased GLUT4 glucose-transporter expression in muscle, enhanced glucose metabolism, and improved insulin sensitivity.[1][2] In animal models, MOTS-c has been studied for preventing diet-induced weight gain and improving metabolic markers via this AMPK-dependent mechanism.
The “exercise mimetic” angle
One reason MOTS-c gets so much attention: it’s described in the literature as an exercise-mimetic, interacting with exercise to regulate PGC-1α and studied as a mitochondrial-encoded regulator of age-dependent physical decline.[2] Its expression itself appears exercise-responsive. That said, human evidence is early and context-dependent — circulating levels don’t map cleanly onto “better metabolism” in every study, so this is a promising-but-unsettled area.
Where it fits
Because it targets mitochondrial and metabolic biology, MOTS-c is often grouped with longevity research compounds. Available research-use-only as MOTS-c (40mg), and across the Mitochondrial & Longevity collection.
Frequently asked questions
What is MOTS-c?
A 16–amino-acid mitochondrial-derived peptide encoded in mitochondrial DNA, studied in research for its role in metabolism via the AMPK pathway.
Why is MOTS-c called an “exercise mimetic”?
Because in research models it activates AMPK and regulates PGC-1α — pathways also engaged by exercise. Human evidence is still early.
Is MOTS-c approved for human use?
No — it’s sold for laboratory and research use only, and much of the data is preclinical.
Related reading
Why Researchers Study NAD+ · What Is NAD+?
About the author
Charles Fowler is the founder and researcher behind Portal to Wellness. After a career in management consulting, he spent the past two years immersed in the wellness and research-compound space — sourcing products, vetting suppliers, and reading the primary literature daily. He isn’t a physician or a scientist, and he’ll tell you so.
How we research our content
Our Research Library articles are written from peer-reviewed scientific literature and reputable references, and we date every article. We don’t make therapeutic, dosing, or “cure” claims, and we flag where the science is preclinical or unsettled.
References
- Kim KH, et al. The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity. Physiological Reports. 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6640593/
- Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging. (Review.) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854231/
All products sold on this website are intended for research and identification purposes only. They are not intended for human dosing, injection, ingestion, or veterinary use. Must be 18 or older to purchase. This content is educational and is not medical advice.
📚 Part of our Energy & Longevity research guide.
MOTS-c — Research-Grade, Research Use Only
Amounts used in the published research
What does exist in humans
| Item | Detail |
|---|---|
| CB4211 (NCT03998514) | A Phase 1a/1b trial of a MOTS-c analog — a different molecule, not MOTS-c. 88 participants, subcutaneous, completed 2021. The registry lists doses only as “Dose 1–6”; no milligram amounts were ever disclosed, no results posted, no peer-reviewed publication. |
| Reynolds 2021 observational | 10 healthy sedentary men, cycle ergometer. MOTS-c was measured in plasma and muscle, not administered. |
| Endogenous blood levels | Roughly 210–222 pg/mL in healthy adults; lower in poorly controlled type 2 diabetes. Absolute values vary a lot between test kits, so cross-study comparison is unreliable. |
Animal studies
| Model | Amount | Route | Schedule |
|---|---|---|---|
| Mouse, high-fat diet (Lee 2015) | 0.5 mg/kg/day | Intraperitoneal | Daily, up to 8 weeks |
| Mouse, glucose tolerance (Lee 2015) | 5 mg/kg/day | Intraperitoneal | Daily, 7 days |
| Mouse, exercise capacity (Reynolds 2021) | 5 and 15 mg/kg/day | Intraperitoneal | Daily, 2 weeks |
| Mouse, healthspan / lifespan | 15 mg/kg/day | Intraperitoneal | 3× per week, life-long from middle age |
| Rat, lung ischemia-reperfusion | 20 mg/kg/day | Intraperitoneal | 5 consecutive days |
| Mouse, colitis | — | Oral vs IP | Oral administration produced no significant improvement; IP did |
In vitro and pharmacokinetics
10 µM is the near-universal working concentration in cell culture (HEK293, C2C12 myoblasts, pancreatic islet cells); adipocyte work also used 50 µM. No sub-micromolar potency range is established.
Half-life: not published. There is no numeric half-life, Cmax, Tmax, AUC or bioavailability figure for MOTS-c in any species. A 2022 review describes the circulating half-life only qualitatively as “relatively short.” The “~80% subcutaneous bioavailability” figure that circulates online has no peer-reviewed source behind it.
Sources
Lee C et al. Cell Metab 2015, foundational MOTS-c paper — PMID 25738459
Reynolds JC et al. Nat Commun 2021, exercise and healthspan — PMID 33473109
Ramanjaneya M et al. Front Endocrinol 2019, circulating levels — PMID 31214116
Cohen P et al. J Clin Invest 2022, review — PMID 35499074
CB4211 analog trial — NCT03998514